share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1：證券上市註冊聲明
美股SEC公告 ·  2024/09/05 04:55

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. has undergone significant corporate developments over the past year, including a merger with Murphy Canyon Acquisition Corp. on September 22, 2023, which led to its listing on The Nasdaq Global Market under the ticker 'CDT'. The company has authorized a substantial issuance of shares, with up to 250,000,000 shares of common stock and 1,000,000 shares of preferred stock as of December 31, 2023. In the legal arena, Conduit Pharmaceuticals faces a claim from Strand Hanson Limited for advisory fees and stock, which the company is prepared to contest. Additionally, the company has engaged in the sale of unregistered securities, including a private placement of units and the issuance of common stock for services and a licensing agreement with AstraZeneca. The company's leadership is protected by indemnification provisions in its corporate charter and under Delaware law. Financial statements for 2023 and 2022 have been audited, revealing concerns about the company's operational continuity, and past financial statements have been restated to correct errors related to merger expenses.
Conduit Pharmaceuticals Inc. has undergone significant corporate developments over the past year, including a merger with Murphy Canyon Acquisition Corp. on September 22, 2023, which led to its listing on The Nasdaq Global Market under the ticker 'CDT'. The company has authorized a substantial issuance of shares, with up to 250,000,000 shares of common stock and 1,000,000 shares of preferred stock as of December 31, 2023. In the legal arena, Conduit Pharmaceuticals faces a claim from Strand Hanson Limited for advisory fees and stock, which the company is prepared to contest. Additionally, the company has engaged in the sale of unregistered securities, including a private placement of units and the issuance of common stock for services and a licensing agreement with AstraZeneca. The company's leadership is protected by indemnification provisions in its corporate charter and under Delaware law. Financial statements for 2023 and 2022 have been audited, revealing concerns about the company's operational continuity, and past financial statements have been restated to correct errors related to merger expenses.
Conduit Pharmaceuticals Inc.在過去一年中進行了重大的公司發展，包括於2023年9月22日與Murphy Canyon Acquisition Corp.合併，導致其在納斯達克全球市場上市，股票代碼爲'CDT'。公司已授權發行大量股票，截至2023年12月31日，共有2.5億股普通股和100萬股優先股。在法律領域，Conduit Pharmaceuticals面臨來自Strand Hanson Limited的諮詢費用和股票的索賠，公司準備進行爭議。此外，公司還進行了非註冊證券的銷售，包括定向增發單位和發行普通股用於服務以及與阿斯利康的許可協議。公司的領導層受到其公司章程以及特拉華州法律的賠償條款的保護。 2023年和2022年的財務報表已進行了審計，揭示了有關公司運營連續性的問題，並且過去的財務報表已進行了重新陳述，以糾正與合併費用有關的錯誤。
Conduit Pharmaceuticals Inc.在過去一年中進行了重大的公司發展，包括於2023年9月22日與Murphy Canyon Acquisition Corp.合併，導致其在納斯達克全球市場上市，股票代碼爲'CDT'。公司已授權發行大量股票，截至2023年12月31日，共有2.5億股普通股和100萬股優先股。在法律領域，Conduit Pharmaceuticals面臨來自Strand Hanson Limited的諮詢費用和股票的索賠，公司準備進行爭議。此外，公司還進行了非註冊證券的銷售，包括定向增發單位和發行普通股用於服務以及與阿斯利康的許可協議。公司的領導層受到其公司章程以及特拉華州法律的賠償條款的保護。 2023年和2022年的財務報表已進行了審計，揭示了有關公司運營連續性的問題，並且過去的財務報表已進行了重新陳述，以糾正與合併費用有關的錯誤。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間